Clinical Trial Update: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme [Phase 2, Phase 3]

View source ↗

Summary

Phase II/III study evaluating high-dose, intermittent sunitinib for recurrent glioblastoma multiforme is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Gbm
• Glioblastoma
• Glioblastoma Multiforme

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Glioblastoma Multiforme, Glioblastoma, Adult | Phase 2, Phase 3 | Status: UNKNOWN